



October 20, 2026

For Immediate Release

Company name: Relo Group, Inc.
Representative: Kenichi Nakamura
Representative Director, CEO
(Code: 8876, Prime Section of TSE)
Contact: Yasushi Kadota
Director, CFO, CIO
(Tel: +81-3-5312-8704)

Notice of Acquisition of Shares of ATIV Medical Pte. Ltd.

Relo Group, Inc. (the “Company”) hereby announces that, as of October 20, 2026, it has resolved to acquire shares of ATIV Medical Pte. Ltd. (“ATIV Medical”) and make it a subsidiary.

1. Purpose and Background of the Acquisition

Amid the increasing overseas expansion of Japanese companies and intensifying global competition, the Group has pursued its “Second Start-Up Period,” which commenced in April 2011, under the missions of supporting non-core operations so that Japanese companies can focus on their core businesses and compete globally, supporting the global expansion of Japanese companies so that they can demonstrate their true potential, and, through these activities, becoming indispensable in the major transformation that Japan is about to undergo. Under these missions, the Group has adopted the vision of creating a comprehensive lifestyle support services industry on a global scale.

ATIV Medical was established in Singapore in 2022. Guided by its vision of building a global healthcare ecosystem that leads with trust and innovation for Japanese communities living overseas, ATIV Medical is a corporate group that provides healthcare services to Japanese expatriates, travelers and others in countries across Southeast Asia.

By providing assignees who may have concerns about selecting medical institutions at their destinations with the medical services offered by ATIV Medical from the pre-departure stage, the Group will be able to establish an integrated value chain covering the period from pre-departure through local life. This is expected to generate significant customer referral synergies for ATIV Medical, originating from the Group’s overseas assignment support business. The Company determined that the creation of these synergies would contribute to enhancing corporate value and therefore decided to make ATIV Medical a subsidiary.

Going forward, by combining the strengths of both companies, the Group will endeavor to improve the quality of services for overseas assignees and realize its vision of creating a comprehensive lifestyle support services industry on a global scale.

2. Overview of the Company to Become a Subsidiary

(1) Company Name	ATIV Medical Pte. Ltd.		
(2) Headquarters	180 Cecil Street, #12-01, Bangkok Bank Building, Singapore 069546		
(3) Representative	Tatsuki Fujii		
(4) Business	Management consulting services for medical institutions		
(5) Capital stock	SGD 2,614,370		
(6) Year of Establishment	April 11, 2022		
(7) Shareholders and ownership	SEKAISHA Inc.	40.1%	
	Toshisumi Inc.	39.1%	
	Tatsuki Fujii	17.8%	
	Melting Pot No. 3 Investment Limited Partnership	2.0%	
	Yuta Igarashi	1.0%	
(8) Relationship with the Listed Company	Capital relationships	n.a.	
	Personnel relationships	n.a.	
	Trade relationships	n.a.	
(9) Consolidated Financial Results and Financial Position for the Past Three Fiscal Years (SGD)			
Fiscal year	FY ended Mar. 2024	FY ended Mar. 2025	FY ended Mar. 2026
Net Assets	2,254,200	3,157,908	3,943,746
Total Assets	2,982,998	4,427,671	6,352,635
Net Assets per Share	0.0083	0.0117	0.0146
Net Sales	4,124,324	8,003,355	10,965,919
Operating Income	296,130	993,413	1,458,813
Ordinary Income	305,410	1,027,603	1,538,095
Profit Attributable to Owners of Parent	295,518	904,775	1,154,139
Net Income per Share	0.0013	0.0033	0.0042
Dividend per Share	0	0	0.0012

3. Overview of the Sellers

The shares will be acquired from two corporate shareholders and three individual shareholders. An overview of the principal sellers is provided below.

(1) SEKAISHA Inc.

(1) Company Name	SEKAISHA Inc.		
(2) Headquarters	5-4-12 Hiroo, Shibuya-ku, Tokyo		
(3) Representative	Yuta Igarashi, Representative Director and COO		
(4) Business	CVC business and education business		
(5) Capital stock	40 million yen		
(6) Year of Establishment	September 2016		
(7) Relationship with the Listed Company	Capital relationships	n.a.	
	Personnel relationships	n.a.	
	Trade relationships	n.a.	
	Status as a Related Party	n.a.	

(2) Toshisumi Inc.

(1) Company Name	Toshisumi Inc.	
(2) Headquarters	5-4-12 Hiroo, Shibuya-ku, Tokyo	
(3) Representative	Maki Sato, Representative Director	
(4) Business	Video production and distribution business	
(5) Capital stock	9.01 million yen	
(6) Year of Establishment	March 22, 2021	
(7) Relationship with the Listed Company	Capital relationships	n.a.
	Personnel relationships	n.a.
	Trade relationships	n.a.
	Status as a Related Party	n.a.

(3) Tatsuki Fujii

(1) Name	Tatsuki Fujii	
(2) Address	Kuala Lumpur, Malaysia	
(3) Relationship between the Listed Company and the Individual	Capital relationships	n.a.
	Personnel relationships	n.a.
	Trade relationships	n.a.
	Status as a Related Party	n.a.

There are no capital, personnel or trade relationships required to be disclosed between the Company and the sellers not listed above, nor do such sellers qualify as related parties of the Company.

4. Number of Shares to Be Acquired, Acquisition Price and Changes in Shareholdings

(1) Number of shares held before the transfer	0 shares (Number of voting rights: 0) (Voting rights ownership ratio: 0%)
(2) Number of shares acquired	242,910,000 shares (Number of voting rights: 242,910,000) (Voting rights ownership ratio: 90.0%)
(3) Acquisition Price	Common shares of ATIV Medical: 1,620 million yen Advisory fees, etc. (estimated): 60 million yen Total (estimated): 1,680 million yen
(4) Number of Shares Held After the Acquisition	242,910,000 shares (Number of voting rights: 242,910,000) (Voting rights ownership ratio: 90.0%)

5. Schedule

(1) Date of Resolution	October 20, 2026
(2) Date of Agreement	October 20, 2026
(3) Closing Date	October 30, 2026 (Scheduled)

6. Effect on Financial Performance

Although the impact of this share acquisition on the Company's consolidated financial performance is currently under review, the Company believes that it will contribute to improved business performance. If any matter requiring disclosure arises, the Company will promptly announce it.